


# People 16 years and older who are severely immunocompromised

Comirnaty (Pfizer) recommended or other mRNA vaccine if required  
AstraZeneca no longer recommended. Primary course can be completed with mRNA vaccine  
Moderna may be used as substitute at any step

## Dose 1

0.3 mls Pfizer (purple top)




Can be shortened to 3 weeks for people at increased risk of severe COVID-19 or in an outbreak response

8 weeks after dose 1

## Dose 2


0.3 mls Pfizer (purple top)



2 months after dose 2

## Dose 3

0.3 mls Pfizer (purple top)




Primary course of COVID-19 vaccine complete

3 months after dose 3

## Booster dose

0.3 mls Pfizer (purple top)




3 months after dose 4

## Winter dose

0.3 mls Pfizer (purple top)



Course completed = total of 5 doses (as of July 2022)




# People 16 years and older

Comirnaty (Pfizer) recommended or other mRNA vaccine if required  
AstraZeneca no longer recommended. Primary course can be completed with mRNA vaccine

## Dose 1

0.3 mls Pfizer (purple top)




Can be shortened to 3 weeks for people at increased risk of severe COVID-19 or in an outbreak response

8 weeks after dose 1

## Dose 2

0.3 mls Pfizer (purple top)




Primary course of COVID-19 vaccine complete

3 months after dose 2

## Booster dose

0.3 mls Pfizer (purple top)



3 months after dose 3

## Winter dose\*

0.3 mls Pfizer (purple top)

A winter dose is recommended for selected population groups:

- Adults 50+
- Residents of aged care or disability care facilities
- Aboriginal and Torres Strait Islander people 50+
- Adults 16 - 64 with a medical condition that increases the risk of severe illness.

A winter dose is available to people aged 30-49 years of age



Course completed = total of 4 doses (as of July 2022)


Course completed = total of 3 doses (as of July 2022)

## People 12 - 15 years who:

- are severely immunocompromised\*
- have a disability with complex health needs
- have complex / multiple health conditions that increase the risk of severe COVID-19

### Dose 1

0.3 mls Pfizer (purple top)




Comirnaty (Pfizer) recommended or other mRNA vaccine if required  
AstraZeneca no longer recommended.  
Primary course can be completed with mRNA vaccine  
Moderna may be used as substitute at any step

8 weeks after dose 1

### Dose 2

0.3 mls Pfizer (purple top)



Can be shortened to 3 weeks for people at increased risk of severe COVID-19 or in an outbreak response



Primary course of COVID-19 vaccine complete

## \*People who are severely immunocompromised ONLY\*

### Dose 3

0.3 mls Pfizer (purple top)

2 months after dose 2




Primary course of COVID-19 vaccine complete

3 months after primary course


### Booster dose

0.3 mls Pfizer (purple top)



Course completed = total of 3\* doses  
\*4 doses for immunocompromised  
(as of June 2022)






# Children 5 - 11 years

**Paediatric Pfizer vaccine recommended  
Note smaller dose and formulation**

## Dose 1

0.2 mls Paediatric Pfizer  
(orange top), 10mcg



**8 weeks after dose 1**

Can be shortened to  
3 weeks for children  
at increased risk of  
severe COVID-19 or  
in an outbreak  
response

## Dose 2

0.2 mls Paediatric Pfizer  
(orange top), 10mcg




**Primary course of COVID-19  
vaccine complete**

## NO BOOSTER DOSE\*

\*Booster doses are not currently recommended for those aged 15 years and under. In this age group, severe COVID-19 is uncommon, and the primary course of COVID-19 vaccines generates a strong immune response, so the benefit from additional doses of vaccine is likely to be small. In addition, there are currently only very limited data on the safety of repeated mRNA vaccine doses in this age group. Further guidance will be provided in this group as more evidence becomes available.



**Course completed = total of 2 doses  
(as of June 2022)**



# Children 5 - 11 years who are severely immunocompromised

Paediatric Pfizer vaccine recommended  
Note smaller dose and formulation

## Dose 1

0.2 mls Paediatric Pfizer (orange top), 10mcg



8 weeks after dose 1

Can be shortened to 3 weeks for children at increased risk of severe COVID-19 or in an outbreak response

## Dose 2

0.2 mls Paediatric Pfizer (orange top), 10mcg



2 months after dose 2



## Dose 3

0.2 mls Paediatric Pfizer (orange top), 10mcg



Primary course of COVID-19 vaccine complete




## NO BOOSTER DOSE\*

\*Booster doses are not currently recommended for those aged 15 years and under. In this age group, severe COVID-19 is uncommon, and the primary course of COVID-19 vaccines generates a strong immune response, so the benefit from additional doses of vaccine is likely to be small. In addition, there are currently only very limited data on the safety of repeated mRNA vaccine doses in this age group. Further guidance will be provided in this group as more evidence becomes available.



Course completed = total of 3 doses (as of June 2022)




## People 12 - 15 years\*

Comirnaty (Pfizer) recommended or other mRNA vaccine if required  
AstraZeneca no longer recommended. Primary course can be completed with mRNA vaccine

### Dose 1


0.3 mls Pfizer (purple top)



8 weeks after dose 1

### Dose 2

0.3 mls Pfizer (purple top)



Can be shortened to 3 weeks for people at increased risk of severe COVID-19 or in an outbreak response



### BOOSTER DOSE\*

Booster doses are not currently recommended for most people aged 15 years and under.

**Booster dose is recommended for selected people aged 12 - 15 years:**

- are severely immunocompromised\*
- have a disability with complex health needs
- have complex / multiple health conditions that increase the risk of severe COVID-19.

Primary course of COVID-19 vaccine complete



Course completed = total of 2 doses\*  
\*3 doses for certain population groups (as of July 2022)